AGEN vs. OYST, STRO, PSTX, ADAP, ATHA, MNKD, INVA, OPK, IRWD, and LXRX
Should you be buying Agenus stock or one of its competitors? The main competitors of Agenus include Oyster Point Pharma (OYST), Sutro Biopharma (STRO), Poseida Therapeutics (PSTX), Adaptimmune Therapeutics (ADAP), Athira Pharma (ATHA), MannKind (MNKD), Innoviva (INVA), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "medical" sector.
Agenus (NASDAQ:AGEN) and Oyster Point Pharma (NASDAQ:OYST) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
Agenus presently has a consensus target price of $70.00, indicating a potential upside of 346.14%. Given Agenus' higher possible upside, equities analysts plainly believe Agenus is more favorable than Oyster Point Pharma.
In the previous week, Agenus had 5 more articles in the media than Oyster Point Pharma. MarketBeat recorded 6 mentions for Agenus and 1 mentions for Oyster Point Pharma. Agenus' average media sentiment score of 0.56 beat Oyster Point Pharma's score of 0.00 indicating that Agenus is being referred to more favorably in the media.
Agenus has a net margin of -154.88% compared to Oyster Point Pharma's net margin of -901.99%. Agenus' return on equity of 0.00% beat Oyster Point Pharma's return on equity.
61.5% of Agenus shares are owned by institutional investors. Comparatively, 96.7% of Oyster Point Pharma shares are owned by institutional investors. 4.6% of Agenus shares are owned by insiders. Comparatively, 17.9% of Oyster Point Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Agenus received 434 more outperform votes than Oyster Point Pharma when rated by MarketBeat users. Likewise, 70.14% of users gave Agenus an outperform vote while only 47.69% of users gave Oyster Point Pharma an outperform vote.
Agenus has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, Oyster Point Pharma has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.
Oyster Point Pharma has lower revenue, but higher earnings than Agenus. Oyster Point Pharma is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.
Summary
Agenus beats Oyster Point Pharma on 11 of the 17 factors compared between the two stocks.
Get Agenus News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
